- Trial phase
- Approved
- Time to market
- Already approved and marketed. FDA approval was August 6, 2024; EMA approval was September 17, 2025.
- Why 4/10
- Voranigo is already approved and commercialized with no pending regulatory decision or pivotal readout scheduled. As a royalty asset for RPRX, its contribution to share price is gradual through quarterly sales growth, not a binary catalyst. The next hard catalyst for RPRX (neladalkib PDUFA on November 27, 2026) is a different drug. ImpactScore is 4 per the rubric for an approved drug with no imminent binary event.
Voranigo has no pending binary catalyst. Investors should track Servier's commercial execution and quarterly royalty receipts reported by RPRX. RPRX's next major catalyst is the November 27, 2026 PDUFA for neladalkib (a different drug), which is unrelated to Voranigo. Voranigo's contribution to RPRX's value will unfold gradually through sales growth and market expansion across its approved territories.
Price Chart
Executive Summary
Voranigo (vorasidenib) is an FDA- and EMA-approved oral targeted therapy for Grade 2 IDH-mutant glioma, developed and marketed by private French company Servier. Royalty Pharma (RPRX) owns the royalty rights, having paid Agios Pharmaceuticals $905 million upfront for a 15% royalty on U.S. net sales up to $1 billion (12% above $1 billion). The drug is already generating revenue for RPRX (cited as a growth driver in Q3 2026 earnings) with peak sales estimated above $1 billion. There is no pending binary catalyst for this drug; its impact on RPRX's stock is gradual through commercial execution rather than a single event.
How It Works
Voranigo is a once-daily pill that blocks two mutant enzymes, IDH1 and IDH2, found in certain slow-growing brain tumors (Grade 2 gliomas). By inhibiting these enzymes, it reduces the production of a cancer-promoting metabolite called 2-HG, which can slow or stop tumor growth. It is the first targeted therapy (not chemotherapy or radiation) approved for this specific type of brain cancer.
Trial Status
Voranigo was approved by the FDA on August 6, 2024, based on the pivotal Phase 3 INDIGO trial, which showed a significant improvement in progression-free survival (median 27.7 months vs. 11.1 months for placebo). The European Commission approved it on September 17, 2025. At ASCO 2026, Servier presented extended follow-up data (over three years) showing median progression-free survival of 44.1 months, confirming durable benefit. The drug is now approved in over 40 countries.
The Two-Sided Case
Upcoming Catalysts
- No pending regulatory decision for Voranigo specifically. Royalty Pharma's next PDUFA date (November 27, 2026) is for a different drug, neladalkib. Continued commercial uptake and quarterly royalty receipts are the ongoing drivers.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Royalty Pharma plc PRESS-RELEASE RPRX ·Originating report